News for $NVLX - (Potential Future Sales of Nuvi
Post# of 734
Posted On: 03/26/2013 1:28:19 PM
News for $NVLX - (Potential Future Sales of Nuvilex, Inc. Cancer Treatments Make Investment in Cell-in-a-Box Worth It)
NEW YORK, NY, Mar 26, 2013 (MARKETWIRE via COMTEX) -- Nuvilex, Inc. (OTCQB:
NVLX) is a small biotechnology company out of Silver Spring, Maryland, but its
future might be anything but small. As the company diligently prepares for its
Phase III pancreatic cancer trials, the almost $30-million the company has
invested in its unique and proprietary living cell encapsulation or
"Cell-in-a-Box" technology could be money well spent given the return in annual
sales that cancer drugs bring in the marketplace.
Nuvilex has about $25-million invested in two independent Phase II clinical
trials in patients with advanced, inoperable pancreatic cancer using the
combination of the widely used anti-cancer drug, ifosfamide, together with
encapsulated cells capable of converting the ifosfamide into its
"cancer-killing" form and in preclinical studies of other applications for the
technology. In addition, the company has put almost another $2-million into
furthering the development of the "Cell-in-a-Box" technology itself.
This is a pretty hefty price tag for such a small biotech, but with the results
the company has seen to date in its two clinical trials, the future looks very
bright. In those trials, the results show that Nuvilex's treatment outperforms
the current standard, Eli Lilly's Gemzar.
Why is this significant to Nuvilex? It's all about the math and right now Gemzar
-- the standard single drug for pancreatic cancer patients -- equals about
$1.4-billion annually to Eli Lilly. That's billion with a B. Cancer drugs are
big business, and those drugs are even bigger business when they work, and when
they extend lives, and so far, Nuvilex's cell encapsulation technology has shown
it does work and it does extend lives.
Before we look at the results that are better than the current standard, let's
look at how the technology works and why, quite frankly, it's better than adding
another drug to a cancer patient's daily routine.
Continue reading the rest of this article at www.stockhousegroup.com/features
About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in
Awareness, Research, and Content Development. The firm offers a platform to CEOs
to develop their story through the press, Research Reports, and CEO Interviews.
At the same time, we're building a library of Research to assist Investors in
their due diligence on micro, small and large cap stocks.
Contact:
Stock House Group
www.stockhousegroup.com 
(0)
(0)